Boston Scientific reported first-quarter 2026 net sales of $5.203 billion, up 11.6% from $4.663 billion a year earlier. On an operational and organic basis, sales rose 9.4% from the prior-year period.
Net income attributable to common stockholders climbed to $1.341 billion, or $0.90 a share, from $674 million, or $0.45 a share, a year ago. Adjusted earnings per share increased to $0.80 from $0.75.
The company’s revenue growth came in within its own outlook. First-quarter sales growth of 11.6% reported and 9.4% operational compared with guidance for 10.5% to 12.0% reported and 8.5% to 10.0% operational. Adjusted EPS of $0.80 landed at the top end of the company’s forecast range of $0.78 to $0.80.
By segment, MedSurg sales rose 7.8% to $1.701 billion from $1.577 billion. Within MedSurg, Endoscopy increased 9.4% to $736 million, Urology rose 2.1% to $646 million, and Neuromodulation jumped 17.4% to $318 million.
Cardiovascular was the larger growth engine, with sales up 13.5% to $3.503 billion from $3.085 billion.
By geography, U.S. sales increased 10.9% to $3.284 billion. EMEA sales rose 10.1% to $932 million, APAC climbed 14.7% to $803 million, and LACA advanced 19.0% to $185 million.
For 2026, Boston Scientific now expects full-year sales growth of 7.0% to 8.5% reported and 6.5% to 8.0% organic. It also raised its adjusted EPS outlook to $3.34 to $3.41.
For the second quarter, the company projected sales growth of 5.5% to 7.5% reported and 5.0% to 7.0% organic, with adjusted EPS of $0.82 to $0.84.
The quarter also included several product and clinical milestones, including positive trial results for Watchman FLX, EKOS, and Farapulse, regulatory approval in China for the Opal HDx mapping system, FDA clearance for the Asurys fluid management system, and the acquisition of Valencia Technologies. As a result of these announcements, the company's shares have moved 0.56% on the market, and are now trading at a price of $70.17. Check out the company's full 8-K submission here.
